Skip to main content
Clinical Trials/NCT04170257
NCT04170257
Unknown
Not Applicable

Performance of White Light, Narrow Band Imaging and Iodine Staining Endoscopy in the Diagnosis of Esophageal Squamous Epithelium Lesions: A Multicenter Clinical Study in China

Peking University Cancer Hospital & Institute5 sites in 1 country10,000 target enrollmentOctober 18, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild Dysplasia of Esophagus
Sponsor
Peking University Cancer Hospital & Institute
Enrollment
10000
Locations
5
Primary Endpoint
Sensitivity of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus
Last Updated
6 years ago

Overview

Brief Summary

The investigators aim to evaluate the performance of Narrow Band Imaging (NBI) endoscopy in Esophageal Squamous Cell Carcinoma (ESCC) screening, as compared to the currently used White Light Endoscopy (WLE) and Lugol's Iodine Staining Endoscopy (ISE). NBI is a simple, safe and non-invasive technique, which can provide real-time optical staining for suspicious lesions. This trial is designated to enroll 10000 participants from five centers located in different regions (North, West and South) in China, which would provide real-world evidence for the recommendation of endoscopic diagnostic technique used in ESCC screening projects.

Registry
clinicaltrials.gov
Start Date
October 18, 2019
End Date
December 31, 2022
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Peking University Cancer Hospital & Institute
Responsible Party
Principal Investigator
Principal Investigator

Yang Ke

Professor

Peking University Cancer Hospital & Institute

Eligibility Criteria

Inclusion Criteria

  • Patients seek for endoscopic examinations at the endoscopy center in any of the five hospitals included in this study
  • Aged 45-69 years
  • Have entire esophagus
  • Provide written informed consent and leave personal identification and contact information

Exclusion Criteria

  • Have contraindications to endoscopic examination (Including but not limited to severe arrhythmia, myocardial infarction, heart failure, hemiplegia, asthma, severe hypertension (≥ 180 / 110mmHg), psychosis, etc )
  • Have a history of drug allergy
  • Have a history of upper gastrointestinal surgery
  • Have a history of radiotherapy or chemotherapy

Outcomes

Primary Outcomes

Sensitivity of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus

Time Frame: 0 days

Sensitivity of WLE, NBI and ISE, taking results from histopathological analysis of the biopsy specimens as the golden standard.

Negative predictive value (NPV) of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus

Time Frame: 0 days

NPV of WLE, NBI and ISE, taking results from histopathological analysis of the biopsy specimens as the golden standard.

Specificity of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus

Time Frame: 0 days

Specificity of WLE, NBI and ISE, taking results from histopathological analysis of the biopsy specimens as the golden standard.

Positive predictive value (PPV) of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus

Time Frame: 0 days

PPV of WLE, NBI and ISE, taking results from histopathological analysis of the biopsy specimens as the golden standard.

Secondary Outcomes

  • Weight of each visualized abnormal feature of lesions(0 days)
  • Discrimination of visualized abnormal features(0 days)

Study Sites (5)

Loading locations...

Similar Trials